Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

CYP2D6 *3 and *4 polymorphism in cancer patients : a study on breast cancer and head and neck cancer (CROSBI ID 479269)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Štefanović, Mario ; Ivanišević, Ana-Maria ; Topić, Elizabeta ; Petrinović, Rajka ; Orešić, V. ; Turić, Marko ; Čurčić, Ivica CYP2D6 *3 and *4 polymorphism in cancer patients : a study on breast cancer and head and neck cancer // Clin Chem Lab Med 1999 ; vol 37 : Abstracts volume, Special supplement / Siest, Gerard (ur.). Milano: Walter de Gruyter, 1999. str. S152-x

Podaci o odgovornosti

Štefanović, Mario ; Ivanišević, Ana-Maria ; Topić, Elizabeta ; Petrinović, Rajka ; Orešić, V. ; Turić, Marko ; Čurčić, Ivica

engleski

CYP2D6 *3 and *4 polymorphism in cancer patients : a study on breast cancer and head and neck cancer

We investigated the association between the most common Cytochrome P450 CYP2D6 null alleles (CYP2D6*3 and CYP2D6*4) in two different tumor types: breast cancer (BC) and head and neck cancer (HNC). Genotyping was performed in 53 controls, 39 HNC, and 53 BC female patients by PCR-SSCP on whole blood DNA. Study results showed allelic frequencies for *3 and *4 alleles in controls to be 0.9% and 17%, respectively ; among them 1.9% *3 and 29.5% *4 heterozygotes, and 2.3% *4 homozygotes. *3 homozygote was not identified among controls. In HNC patients, allelic frequencies for *3 and *4 alleles were 1.3% and 21.9%, respectively ; out of which 2.6% and 43.8% were heterozygotes for *3 and *4 allele, respectively. We observed no homozygotes. Among BC patients, no *3 allele was found, whereas the frequency of *4 allele was 20.7%. There were 26.8% of heterozygotes and 7.3% of homozygotes for *4 allele. The difference in *4 genotypes comparing the patients to controls was: p=0.05(Chi) for HNC patients and p=0.22(Chi) for BC patients. To confirm our findings suggesting that CYP2D6*4 allele could be a contributory factor for the development of different tumors, further study on larger groups is needed.

CYP2D6 polymorphism; cancer

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

S152-x.

1999.

objavljeno

Podaci o matičnoj publikaciji

Clin Chem Lab Med 1999 ; vol 37 : Abstracts volume, Special supplement

Siest, Gerard

Milano: Walter de Gruyter

Podaci o skupu

IFCC-World lab, 17th International and 13th European Congress of Clinical Chemistry and Laboratory Medicine

poster

06.06.1999-11.06.1999

Firenca, Italija

Povezanost rada

Temeljne medicinske znanosti